ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2002

Cost-Effectiveness Analysis of Sequential Treatment with Abaloparatide Followed by Alendronate in US Women and Men with Multiple Previous Fractures

Mickael Hiligsmann1, Stuart Silverman2, Andrea J Singer3, Yamei Wang4, Leny Pearman4, John Caminis4 and Jean-Yves Reginster5, 1Maastricht University, Maastricht, Netherlands, 2Cedars-Sinai Medical Center and UCLA School of Medicine, Los Angeles, CA, 3MedStar Georgetown University Hospital, Washington, DC, 4Radius Health, Inc., Boston, MA, 5University of Liège, Liège, Belgium

Meeting: ACR Convergence 2023

Keywords: Cost-Effectiveness, Economics, Fracture, Health Services Research, osteoporosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1996–2018) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with multiple previous fractures are at very high risk of subsequent fractures. Common treatment strategies for these patients include generic alendronate (ALN) monotherapy or sequential therapy with an anabolic agent first (such as abaloparatide [ABL] or teriparatide [TPTD]) followed by generic ALN. Due to mounting pressure on healthcare systems, cost-effectiveness analyses are increasingly important to support decision makers in efficient healthcare resource allocation. This study was designed to evaluate the cost-effectiveness of sequential treatment with ABL followed by ALN compared to relevant alternative strategies in women and men with two previous fractures in the United States (US).

Methods: A lifetime microsimulation model estimated the US healthcare costs (in 2022 dollars) and quality-adjusted life years (QALYs) associated with sequential ABL/ALN and three relevant comparators: (1) a similar sequence beginning with unbranded TPTD; (2) generic ALN monotherapy; and (3) no treatment, which must be included as a comparator as many patients at very high fracture risk do not receive an osteoporosis medication. The analyses were conducted in men and women aged 50 to 90 years with two previous fractures and densitometric osteoporosis (bone mineral density T-score ≤−2.5). Sequential ABL/ALN is considered dominant if it is associated with more QALYs for lower costs than the comparator strategy, and is cost-effective if the cost per QALY gained falls below the US cost-effectiveness threshold of $150,000 per QALY gained. Various scenarios and sensitivity analyses were conducted to investigate uncertainty, including analyses on gender, age (50-90 years), and site of previous fractures.

Results: In both US women and men aged 50-90 years, sequential ABL/ALN was dominant compared to sequential unbranded TPTD/ALN. The costs per QALY gained of sequential ABL/ALN compared to no treatment were below the cost-effectiveness threshold in men aged ≥50 years with two previous fractures, in women aged ≥55 years with two previous fractures, and those aged ≥50 years with history of hip or vertebral fracture. When compared to ALN monotherapy, the costs per QALY gained of sequential ABL/ALN were estimated at $82,288 and $111,584 in men and women aged 70 years with two previous fractures, respectively. These numbers decreased to $35,283 and $66,707 with history of hip fracture. Sequential ABL/ALN was further cost-effective in men ≥50 years with two previous fractures, in women ≥55 years with two previous fractures including a hip or vertebral fracture, and in women ≥65 years for other types of fractures.

Conclusion: Sequential ABL/ALN is dominant in all analyses completed compared to unbranded TPTD/ALN and is cost-effective compared to generic ALN monotherapy in men aged ≥50 years, in women aged ≥55 years with history of hip or vertebral fracture, and in women aged ≥65 years with other fracture types.


Disclosures: M. Hiligsmann: Amgen, 5, IBSA, 6, Mylan Pharmaceuticals, 6, Radius Health, Inc., 5, UCB, 2; S. Silverman: Amgen, 2, 5, Radius Health, Inc, 2, 5; A. Singer: Agnovos, 2, Amgen, 2, 6, Radius Health, Inc, 2, 6, Radius Health, Inc., 5, UCB, 2, 5; Y. Wang: Radius Health, Inc, 3; L. Pearman: Radius Health, Inc, 3; J. Caminis: Radius Health, Inc, 12, Former Employee; J. Reginster: CNIEL, 5, 6, Dairy Research Council, 6, IBSA-Genevrier, 2, 5, 6, Mylan, 5, 6, Pierre Fabre, 1, Radius Health, Inc, 2, 5, 5, Teva, 2, 6.

To cite this abstract in AMA style:

Hiligsmann M, Silverman S, Singer A, Wang Y, Pearman L, Caminis J, Reginster J. Cost-Effectiveness Analysis of Sequential Treatment with Abaloparatide Followed by Alendronate in US Women and Men with Multiple Previous Fractures [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/cost-effectiveness-analysis-of-sequential-treatment-with-abaloparatide-followed-by-alendronate-in-us-women-and-men-with-multiple-previous-fractures/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cost-effectiveness-analysis-of-sequential-treatment-with-abaloparatide-followed-by-alendronate-in-us-women-and-men-with-multiple-previous-fractures/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology